IGeneX Inc.

556 Gibraltar Drive
Milpitas, CA 95035
T: (800) 832-3200
F: (408) 935-8272

www.igenex.com

Laboratory Director: Jyotsna S. Shah, Ph.D.

CLIA: 05D0643914
CALIFORNIA: CLF 4033
NPI: 1396837605

REFERRING PHYSICIAN

IGENEX, INC.
556 GIBRALTAR RD
MILPITAS, CA 95035

SAMPLE REPORT, TBD4IBL
DOB: 01/01/2001
Gender: FEMALE
Accession: B059332
Patient ID: 296830

Collected:	06/17/2026 UNK
Received:	06/18/2026 07:31
Reported:	06/18/2026 07:34
Reprinted:	06/18/2026 07:34
Amended:	
Corrected:	

TEST	SPECIMEN	RESULT	REFERENCE RANGE	UNITS

BORRELIOSIS - Lyme Disease

Lyme ImmunoBlot IgM	Serum	
IGX Criteria:		Negative
CDC/NYS Criteria:		Negative

***

[REVISED REPORT: EFFECTIVE APRIL 10, 2019]

Lyme ImmunoBlot IgM detects antibodies to B. burgdorferi strains and species

Band (kDa)	23*	31*	34*	39*	41*	93
Intensity	-	-	-	-	-	-

Band Intensity: Positive: + to ++++, Indeterminate: Ind, Negative: (-)

INTERPRETATION	IGX CRITERIA	CDC/NYS CRITERIA
Positive	2 or more of the starred bands are present (+): 23*, 31*, 34*, 39*, 41* kDa	2 or more of the following bands are present (+): 23*, 39*, 41* kDa
Negative	Does not meet IGX criteria for a positive.	Does not meet CDC/NYS criteria for a positive.

LIMITATION: Bands 31* and 34* kDa are present in Lyme vaccinated patients. Viral antibodies cross react with the 93 kDa antigen.

Testing performed at IGeneX 556 Gibraltar Drive Milpitas CA 95035 (800) 832-3200

Diagnosis should not be based on laboratory results alone. Results should be interpreted in conjunction with clinical symptoms and patient history.

NOTE: Western Blots, ImmunoBlots, Lyme Dot Blot, Epitope, PCR, IFA, FISH, C. pneumoniae IgG/IgA, CD57, IGXSpot, Broad Coverage Antibody, COVID-19 Test - These tests were developed and their performance characteristics determined by IGeneX, Inc. They have not been cleared or approved by the FDA. The FDA has determined that such approval is not necessary. These tests are used for clinical purposes and should not be regarded as investigational or for research. IGeneX, Inc. is licensed by CMS and NYS to perform high complexity clinical laboratory testing.

DOB: 01/01/2001
Gender: FEMALE Accession: B059332
Patient ID: 296830
Physician: IGENEX, INC. Client: 1

Collected: 06/17/2026 UNK
Received: 06/18/2026 07:31
Reported: 06/18/2026 07:34
Reprinted: 06/18/2026 07:34
Amended:
Corrected:

TEST	SPECIMEN	RESULT	REFERENCE RANGE	UNITS

TEST	SPECIMEN	RESULT	REFERENCE RANGE	UNITS

LYME IMMUNOBLOT IGM SPECIATION

Revised report:06-09-22

B. burgdorferi US(genus)	Serum	Negative	
B. burgdorferi US Spp	Serum	Negative	

BbSs: Borrelia burgdorferi sensu stricto includes but not limited to B. burgdorferi B31 and B. burgdorferi 297.

BbSl: Borrelia burgdorferi sensu lato includes but not limited to B. mayonii and B. californiensis.

B. burgdorferi European(genus)	Serum	Negative	
B. burgdorferi European Spp	Serum	Negative	

Borrelia burgdorferi European species include but not limited to B. afzelii, B. garinii, B. spielmanii and B. valaisiana.

Testing performed at IGeneX 556 Gibraltar Drive Milpitas CA 95035 (800) 832-3200

Diagnosis should not be based on laboratory results alone. Results should be interpreted in conjunction with clinical symptoms and patient history.

NOTE: Western Blots, ImmunoBlots, Lyme Dot Blot, Epitope, PCR, IFA, FISH, C. pneumoniae IgG/IgA, CD57, IGXSpot, Broad Coverage Antibody, COVID-19 Test - These tests were developed and their performance characteristics determined by IGeneX, Inc. They have not been cleared or approved by the FDA. The FDA has determined that such approval is not necessary. These tests are used for clinical purposes and should not be regarded as investigational or for research. IGeneX, Inc. is licensed by CMS and NYS to perform high complexity clinical laboratory testing.

SAMPLE REPORT, TBD4IBL
DOB: 01/01/2001
Gender: FEMALE Accession: B059332
Patient ID: 296830
Physician: IGENEX, INC. Client: 1

Collected: 06/17/2026 UNK
Received: 06/18/2026 07:31
Reported: 06/18/2026 07:34
Reprinted: 06/18/2026 07:34
Amended:
Corrected:

TEST	SPECIMEN	RESULT	REFERENCE RANGE	UNITS
Lyme ImmunoBlot IgG	Serum			
IGX Criteria:		Negative		
CDC/NYS Criteria:		Negative		

***
[REVISED REPORT: EFFECTIVE APRIL 10, 2019]

Lyme ImmunoBlot IgG detects antibodies to B. burgdorferi strains and species

Band (kDa)	**18**	**23***	**28**	**30**	**31***	**34***	**39***	**41***	**45**	**58**	**66**	**93***
Intensity	-	-	-	-	-	-	-	-	-	-	-	-

Band Intensity: Positive: + to ++++, Indeterminate: Ind, Negative: (-)

INTERPRETATION	**IGX CRITERIA**	**CDC/NYS CRITERIA**
Positive	2 or more of the starred bands are present (+): 23*, 31*, 34*, 39*, 41*, 93* kDa	5 or more of the following bands are present (+): 18, 23*, 28, 30, 39*, 41*, 45, 58, 66, 93* kDa
Negative	Does not meet IGX criteria for a positive.	Does not meet CDC/NYS criteria for a positive.

LIMITATION: Bands 31* and 34* kDa are present in Lyme vaccinated patients. Viral antibodies cross react with the 93 kDa antigen.

Testing performed at IGeneX 556 Gibraltar Drive Milpitas CA 95035 (800) 832-3200

Diagnosis should not be based on laboratory results alone. Results should be interpreted in conjunction with clinical symptoms and patient history.

NOTE: Western Blots, ImmunoBlots, Lyme Dot Blot, Epitope, PCR, IFA, FISH, C. pneumoniae IgG/IgA, CD57, IGXSpot, Broad Coverage Antibody, COVID-19 Test - These tests were developed and their performance characteristics determined by IGeneX, Inc. They have not been cleared or approved by the FDA. The FDA has determined that such approval is not necessary. These tests are used for clinical purposes and should not be regarded as investigational or for research. IGeneX, Inc. is licensed by CMS and NYS to perform high complexity clinical laboratory testing.

DOB: 01/01/2001
Gender: FEMALE Accession: B059332
Patient ID: 296830
Physician: IGENEX, INC. Client: 1

Collected: 06/17/2026 UNK
Received: 06/18/2026 07:31
Reported: 06/18/2026 07:34
Reprinted: 06/18/2026 07:34
Amended:
Corrected:

TEST	SPECIMEN	RESULT	REFERENCE RANGE	UNITS
LYME IMMUNOBLOT IGG SPECIATION				
Revised report:06-09-22				
B. burgdorferi US(genus)	Serum	Negative		
B. burgdorferi US spp	Serum	Negative		
BbSs: Borrelia burgdorferi sensu stricto includes but not limited to B. burgdorferi B31 and B. burgdorferi 297.				
BbSl: Borrelia burgdorferi sensu lato includes but not limited to B. mayonii and B. californiensis.				
B. burgdorferi European(genus)	Serum	Negative		
B. burgdorferi European Spp	Serum	Negative		
Borrelia burgdorferi European species include but not limited to B. afzelii, B. garinii, B. spielmanii and B. valaisiana.				
LYME SCREEN IMMUNOASSAY IGM				
Lyme Screen IgM	Serum	Negative	Negative	
** FOR POSITIVE RESULT, TESTING BY IMMUNOBLOT IGM OR IGG IS RECOMMENDED. rev.03/12/25*				
LYME SCREEN IMMUNOASSAY IGG				
Lyme Screen IgG	Serum	Negative	Negative	
** FOR POSITIVE RESULT, TESTING BY IMMUNOBLOT IGM OR IGG IS RECOMMENDED. rev.03/12/25*				

BORRELIOSIS- Relapsing Fever Borrelia

TBRF Borrelia ImmunoBlot IgM				
TBRF Borrelia genus ImmunoBlot IgM	Serum	Negative	Positive:	Detected 2 or more TBRF Borrelia

Testing performed at IGeneX 556 Gibraltar Drive Milpitas CA 95035 (800) 832-3200

Diagnosis should not be based on laboratory results alone. Results should be interpreted in conjunction with clinical symptoms and patient history.

NOTE: Western Blots, ImmunoBlots, Lyme Dot Blot, Epitope, PCR, IFA, FISH, C. pneumoniae IgG/IgA, CD57, IGXSpot, Broad Coverage Antibody, COVID-19 Test - These tests were developed and their performance characteristics determined by IGeneX, Inc. They have not been cleared or approved by the FDA. The FDA has determined that such approval is not necessary. These tests are used for clinical purposes and should not be regarded as investigational or for research. IGeneX, Inc. is licensed by CMS and NYS to perform high complexity clinical laboratory testing.

DOB: 01/01/2001
Gender: FEMALE Accession: B059332
Patient ID: 296830
Physician: IGENEX, INC. Client: 1

Collected: 06/17/2026 UNK
Received: 06/18/2026 07:31
Reported: 06/18/2026 07:34
Reprinted: 06/18/2026 07:34
Amended:
Corrected:

TEST	SPECIMEN	RESULT	REFERENCE RANGE	UNITS
			species-specific antibodies. Indeterminate: Detected only 1 TBRF Borrelia species-specific antibody. Negative: No TBRF Borrelia specific antibody detected.	

** TBRF ImmunoBlot IgM detects antibodies to Borrelia hermsii, B. turicatae, B. miyamotoi and TBRF Borrelia species.*

TBRF Borrelia ImmunoBlot IgM Species			
B. miyamotoi	Serum	Negative	
B. hermsii	Serum	Negative	
B. turicatae	Serum	Negative	
TBRF Borrelia spp	Serum	Negative	
TBRF Borrelia ImmunoBlot IgG			
TBRF Borrelia genus ImmunoBlot IgG	Serum	Negative	Positive: Detected 2 or more TBRF Borrelia species-specific antibodies. Indeterminate: Detected only 1 TBRF Borrelia species-specific antibody. Negative: No TBRF Borrelia specific antibody detected.

** TBRF ImmunoBlot IgG detects antibodies to Borrelia hermsii, B. turicatae, B. miyamotoi and TBRF Borrelia species. rev101624*

TBRF Borrelia ImmunoBlot IgG Species		
B. miyamotoi	Serum	Negative
B. hermsii	Serum	Negative
B. turicatae	Serum	Negative
TBRF Borrelia spp	Serum	Negative

BABESIOSIS

DOB: 01/01/2001
Gender: FEMALE Accession: B059332
Patient ID: 296830
Physician: IGENEX, INC. Client: 1

Collected: 06/17/2026 UNK
Received: 06/18/2026 07:31
Reported: 06/18/2026 07:34
Reprinted: 06/18/2026 07:34
Amended:
Corrected:

TEST	SPECIMEN	RESULT	REFERENCE RANGE	UNITS
BABESIA IMMUNOBLOT IGM				
Babesia ImmunoBlot IgM(genus)	Serum	Negative	Positive: Presence of 2 or more Babesia specific antibodies. Negative: Presence of only 1 or no Babesia specific antibody.	
** Babesia ImmunoBlot test detects specific IgM antibodies to Babesia species, including but not limited to B. microti, B. duncani and B. divergens.*				
B. microti ImmunoBlot IgM	Serum	Negative		
B. duncani ImmunoBlot IgM	Serum	Negative		
Babesia spp.	Serum	Negative		
Limitations: *Negative test result does not exclude possibility of Babesia infection, may retest in 6-8 weeks.* *Results should be interpreted in conjunction with clinical symptoms and other laboratory findings.*				
BABESIA IMMUNOBLOT IGG				
Babesia ImmunoBlot IgG(genus)	Serum	Negative	Positive: Presence of 2 or more Babesia specific antibodies. Negative: Presence of only 1 or no Babesia specific antibody.	
** Babesia ImmunoBlot test detects specific IgG antibodies to Babesia species, including but not limited to B. microti, B. duncani and B. divergens.*				
B. microti ImmumoBlot IgG	Serum	Negative		
B. duncani ImmunoBlot IgG	Serum	Negative		
Babesia spp.	Serum	Negative		
Limitations:				

Testing performed at IGeneX 556 Gibraltar Drive Milpitas CA 95035 (800) 832-3200

Diagnosis should not be based on laboratory results alone. Results should be interpreted in conjunction with clinical symptoms and patient history.

NOTE: Western Blots, ImmunoBlots, Lyme Dot Blot, Epitope, PCR, IFA, FISH, C. pneumoniae IgG/IgA, CD57, IGXSpot, Broad Coverage Antibody, COVID-19 Test - These tests were developed and their performance characteristics determined by IGeneX, Inc. They have not been cleared or approved by the FDA. The FDA has determined that such approval is not necessary. These tests are used for clinical purposes and should not be regarded as investigational or for research. IGeneX, Inc. is licensed by CMS and NYS to perform high complexity clinical laboratory testing.

DOB: 01/01/2001
Gender: FEMALE Accession: B059332
Patient ID: 296830
Physician: IGENEX, INC. Client: 1

Collected: 06/17/2026 UNK
Received: 06/18/2026 07:31
Reported: 06/18/2026 07:34
Reprinted: 06/18/2026 07:34
Amended:
Corrected:

TEST	SPECIMEN	RESULT	REFERENCE RANGE	UNITS
Negative test result does not exclude possibility of Babesia infection, may retest in 6-8 weeks. Results should be interpreted in conjunction with clinical symptoms and other laboratory findings.				
EHRLICHIOSIS				
HME IFA - IgM	Serum	<20	< 20 : Negative = 20 : May or may not indicate active infection >=40 : Indicates active infection	Titer
HME IFA - IgG	Serum	<40	< 40 : Negative < 160 : May or may not suggest active infection >=160 : Indicates active infection	Titer
ANAPLASMOSIS				
HGA IFA - IgM	Serum	<20	< 20 : Negative = 20 : May or may not indicate active infection >=40 : Indicates active infection	Titer
HGA IFA - IgG	Serum	<40	< 40 : Negative < 160 : May or may not suggest active infection >=160 : Indicates active infection	Titer
BARTONELLOSIS				

Testing performed at IGeneX 556 Gibraltar Drive Milpitas CA 95035 (800) 832-3200

Diagnosis should not be based on laboratory results alone. Results should be interpreted in conjunction with clinical symptoms and patient history.

NOTE: Western Blots, ImmunoBlots, Lyme Dot Blot, Epitope, PCR, IFA, FISH, C. pneumoniae IgG/IgA, CD57, IGXSpot, Broad Coverage Antibody, COVID-19 Test - These tests were developed and their performance characteristics determined by IGeneX, Inc. They have not been cleared or approved by the FDA. The FDA has determined that such approval is not necessary. These tests are used for clinical purposes and should not be regarded as investigational or for research. IGeneX, Inc. is licensed by CMS and NYS to perform high complexity clinical laboratory testing.

DOB: 01/01/2001
Gender: FEMALE Accession: B059332
Patient ID: 296830
Physician: IGENEX, INC. Client: 1

Collected: 06/17/2026 UNK
Received: 06/18/2026 07:31
Reported: 06/18/2026 07:34
Reprinted: 06/18/2026 07:34
Amended:
Corrected:

TEST	SPECIMEN	RESULT	REFERENCE RANGE	UNITS
BARTONELLA IMMUNOBLOT IGM				
Bartonella genus	Serum	Negative	Positive: Detected 2 or more Bartonella genus or species-specific antibody. Indeterminate: Detected only 1 Bartonella genus or species- specific antibody. Negative: No Bartonella specific antibody detected.	
B. elizabethae	Serum	Negative		
B. vinsonii	Serum	Negative		
B. henselae	Serum	Negative		
B. quintana	Serum	Negative		
Bartonella species	Serum	Negative		
Report revision: Effective 11-15-2022				
Bartonella ImmunoBlot test detects specific antibodies to Bartonella species, including but not limited to B.elizabethae, B. vinsonii, B.henselae, B.quintana, B.bacilliformis, B.clarridgeiae, B. grahamii, B.koehlerae, B.washoensis and B.rochalimae.				
BARTONELLA IMMUNOBLOT IGG				
Bartonella genus	Serum	Negative	Positive: Detected 2 or more Bartonella genus or species-specific antibody. Indeterminate: Detected only 1 Bartonella genus or species- specific antibody. Negative: No Bartonella specific antibody detected.	
B. elizabethae	Serum	Negative		
B. vinsonii	Serum	Negative		
B. henselae	Serum	Negative		
B. quintana	Serum	Negative		
Bartonella species	Serum	Negative		
Report revision: Effective 11-15-2022				
Bartonella ImmunoBlot test detects specific antibodies to Bartonella species, including but not limited to B.elizabethae, B.				

Testing performed at IGeneX 556 Gibraltar Drive Milpitas CA 95035 (800) 832-3200

Diagnosis should not be based on laboratory results alone. Results should be interpreted in conjunction with clinical symptoms and patient history.

NOTE: Western Blots, ImmunoBlots, Lyme Dot Blot, Epitope, PCR, IFA, FISH, C. pneumoniae IgG/IgA, CD57, IGXSpot, Broad Coverage Antibody, COVID-19 Test - These tests were developed and their performance characteristics determined by IGeneX, Inc. They have not been cleared or approved by the FDA. The FDA has determined that such approval is not necessary. These tests are used for clinical purposes and should not be regarded as investigational or for research. IGeneX, Inc. is licensed by CMS and NYS to perform high complexity clinical laboratory testing.

SAMPLE REPORT, TBD4IBL

TEST	SPECIMEN	RESULT	REFERENCE RANGE	UNITS

vinsonii, B.henselae, B.quintana, B.bacilliformis, B.clarridgeiae, B. grahamii, B.koehlerae, B.washoensis and B.rochalimae.

RICKETTSIOSIS

R. rickettsii IFA - IgG	Serum	<40	< 40 : Negative < 160 : May or may not suggest active infection >=160 : Indicates active infection	Titer
R. typhi IFA - IgG	Serum	<40	< 40 : Negative < 160 : May or may not suggest active infection >=160 : Indicates active infection	Titer

End of Report